AlloRx Stem Cell therapy is under clinical development by Vitro Biopharma and currently in Phase II for Inflammation. According to GlobalData, Phase II drugs for Inflammation have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AlloRx Stem Cell therapy’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AlloRx Stem Cell therapy overview

Stem cell therapy is under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), post-acute sequelae of covid 2019 (pasc or long covid), osteoarthritis, Pitt Hopkins Syndrome (PTHS), Alzheimer's Disease, Parkinson's Disease, autism, systemic lupus erythematosus, Crohn's disease, multiple sclerosis, stroke, traumatic brain injury, kidney disease and inflammation. It is administered through intravenous route. The therapeutic candidate comprises of allogeneic, umbilical cord derived, mesenchymal stem cells (AlloRx stem cells).

It was also under development for the treatment of unspecified musculoskeletal disorders.

Vitro Biopharma overview

Vitro Biopharma formerly Vitro Diagnostics, is a provider of diagnostic products that develops and commercializes adult stem cell products. The company provides products includes cell culture media, cell lines and cell measurement tools, among others. It offers cell lines such as umbilical cord blood derived mscs, adipose derived mscs, fluorescent labeled mscs and cancer associated fibroblasts, differentiated mscs, and others. Vitro Biopharma provides formulations of MSCs and primary cell cultures with numerous competitive advantages. The company provides functional cell-based assays for drug-development, drug-discovery, and stem cell research and offers varieties of biomarker panels which include cardiovascular, neurological, immunology, oncology and toxicity, among others. Vitro Biopharma is headquartered in Golden, Colorado, the US.

For a complete picture of AlloRx Stem Cell therapy’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.